Comparative Market Analysis of Generic and Branded Pharmaceuticals in the Indian Healthcare Sector
International Journal of Pharmacological and Pharmaceutical Innovations (IJPPI) · 27.06.2026 · 13
DOI: 10.67540/ijppi.v1.i2.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Pharmacological and Pharmaceutical Innovations (IJPPI), online erschienen am 27.06.2026. Verfasst von MOHD. ARIF und 5 weiteren Autor:innen. Die Arbeit nennt 44 Literaturangaben.
Abstract (Originalsprache)
Background
The pharmaceutical industry plays a pivotal role in enhancing healthcare delivery by ensuring the availability of safe, effective, and high-quality medicines. particularly in developing countries like India, where affordability remains a major concern. The ongoing debate between branded and generic medicines significantly impacts healthcare delivery and cost management.
Objective
This research aims to estimate the comparative landscape of branded and generic medicines in India, focusing on market trends, pricing differences, stakeholder perceptions, and policy frameworks.
Methods
A systematic analytical approach was adopted using secondary data from government reports, published literature, and industry sources. The study evaluates drug pricing, availability, prescription patterns, and consumer awareness to assess market penetration and acceptance.
Results
Findings indicate a substantial price difference between branded and generic medicines, with generics being more affordable. However, branded drugs continue to dominate the market due to prescriber preference, perceived quality concerns, and strong marketing strategies. Limited awareness and trust among consumers also hinder the widespread adoption of generics.
Conclusion
Generic medicines offer a cost-effective solution to improve healthcare accessibility in India, yet their utilization remains suboptimal. Strengthening regulatory enforcement, increasing awareness, and promoting rational prescribing practices are essential to enhance the acceptance and use of generic medicines. This study is based exclusively on secondary data analysis of government reports, published literature, market databases, and policy documents. Key findings demonstrated that branded medicines were approximately 10-20 times more expensive than generic alternatives, with price differences exceeding 1000% for several commonly prescribed medicines. Branded generics accounted for nearly 80% of the retail market, while public generic medicine schemes contributed only a small share of total utilization.
Zitieren
APA
ARIF, M., MISHRA, R., MAZUMDER, R., MAZUMDER, A., VARSHNEY, S., & RANI, A. (2026). Comparative Market Analysis of Generic and Branded Pharmaceuticals in the Indian Healthcare Sector. International Journal of Pharmacological and Pharmaceutical Innovations (IJPPI), 13. https://doi.org/10.67540/ijppi.v1.i2.014
Vancouver
ARIF M, MISHRA R, MAZUMDER R, MAZUMDER A, VARSHNEY S, RANI A. Comparative Market Analysis of Generic and Branded Pharmaceuticals in the Indian Healthcare Sector. International Journal of Pharmacological and Pharmaceutical Innovations (IJPPI). 2026:13. doi:10.67540/ijppi.v1.i2.014
BibTeX
@article{ARIF2026,
author = {ARIF, MOHD. and MISHRA, RAKHI and MAZUMDER, RUPA and MAZUMDER, AVIJIT and VARSHNEY, SHRUTI and RANI, ANJNA},
title = {Comparative Market Analysis of Generic and Branded Pharmaceuticals in the Indian Healthcare Sector},
journal = {International Journal of Pharmacological and Pharmaceutical Innovations (IJPPI)},
year = {2026},
pages = {13},
doi = {10.67540/ijppi.v1.i2.014}
}
EUVIMED